Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib in Refractory Colorectal Cancer
NCT02277093Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pacritinib in colorectal cancer (CRC), sponsored by Washington University School of Medicine. Primary endpoint: Progression-free Survival. Started Sep 2015; status: terminated.
02
Drugs
pacritinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02277093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02277093.